| Bioactivity | EPI-589, a quinone derivative, is a safe and well tolerated oxidoreductase enzyme inhibitor. EPI-589 has the potential for the treatment of amyotrophic lateral sclerosis (ALS)[1]. | ||||||||||||
| Target | IC50: oxidoreductase enzyme | ||||||||||||
| In Vivo | EPI-589 exhibits a significant improvement in cerebrospinal fluid (CSF) and plasma-based biomarkers known to be associated with neuroinflammation and ALS disease progression[2]. | ||||||||||||
| Name | EPI-589 | ||||||||||||
| CAS | 1147883-03-1 | ||||||||||||
| Formula | C14H19NO4 | ||||||||||||
| Molar Mass | 265.30 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. BioElectron’s EPI-589 Shows Positive Results in ALS Patients in Phase 2a Trial [2]. Phase IIa trial of EPI-589 in ALS shows improvement in CSF |